Cooperative Agreement U01CA294548
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.353
Assistance Type
Cooperative Agreement
Place of Performance
Portland, OR 97239, USA
Similar Awards
This Cooperative Agreement, awarded by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot federal grant program (CFDA 93.353), will fund the construction of a three-dimensional (3D) multimodal molecular atlas of colorectal cancer (CRC) across different ages of onset. The $1,063,411 award to Vanderbilt University will support spatial mapping of tumor progression from precancerous to cancerous states, utilizing cutting-edge technologies such as...
The National Cancer Institute (NCI) awarded a 5-year, $654,197 Project Grant (CFDA 93.396 - Cancer Biology Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on pancreatic ductal adenocarcinoma (PDAC). The key objectives are to: Define the molecular subtypes of PDAC that respond to standard-of-care chemotherapies like FOLFIRINOX and gemcitabine + Abraxane. Elucidate how different stromal subtypes within patient-derived...
This Cooperative Agreement award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) will fund the establishment of the Human Prostate Tumor Atlas Center (HPTAC) at Washington University in St. Louis. The $1,032,520 award, effective September 1, 2024 through August 31, 2029, will support the development of a molecularly resolved spatial atlas of prostate cancer (PCa). The atlas will integrate multi-omics, imaging, and...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Johns Hopkins University provides $653,819 to develop an early detection blood-based screening test for pancreatic cancer, called "PancSeek", and to create integrated risk models, called "PancDetect", that leverage clinical, genomic, molecular, and imaging data to guide personalized surveillance plans for high-risk individuals. The overarching goal is...
The National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $585,458 Cooperative Agreement to Baylor College of Medicine to further validate a mass spectrometry-based proteomic assay for early detection of pancreatic ductal adenocarcinoma (PDAC). The project aims to: 1) determine the performance characteristics and robustness of the assay for clinical utilization; 2) refine the assay accuracy and thresholds for PDAC detection...
This Cooperative Agreement award, with a total funding of $1,069,873, was granted by the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353). The award aims to establish the Center for Gastric Pre-Cancer Atlas of Multidimensional Evolution in 3D (GAME3D) to develop a multimodal, single-cell, dynamic, and 3D spatial atlas of normal-appearing gastric mucosa, early precancerous lesions, and advanced gastric cancer in individuals with...
This Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $1,199,514 to develop a comprehensive and scalable multimodal AI model, termed "PRECISE", that fuses imaging and non-imaging data to enable early detection of pancreatic ductal adenocarcinoma (PDAC). The project aims to create deep learning models that can segment imaging biomarkers from abdominal CT scans and combine them with clinical data...
This $1,128,990 Cooperative Agreement award from the National Cancer Institute (CFDA 93.353 - 21st Century Cures Act - Beau Biden Cancer Moonshot) will fund the Myeloma Multidimensional Precancer Atlas (MMPCA) project at the Dana-Farber Cancer Institute. The project aims to construct a comprehensive spatial and temporal atlas of precursor stages of multiple myeloma (MM) to understand genomic and microenvironmental alterations across the disease spectrum. Key objectives include: Mapping spatial...
This $471,675 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund research at Oregon Health & Science University to develop a nanoparticle-based blood test to distinguish pancreatic cancer from benign pancreatic disease. The researchers will use high conductance dielectrophoresis technology to simultaneously recover different types of cancer-derived...
The National Cancer Institute (NCI) awarded a $1,004,570 Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot (CFDA 93.353) program to The University of Texas MD Anderson Cancer Center (MD Anderson) for a 5-year project. The project aims to construct a 3D spatial atlas of high-grade serous ovarian cancer (HGSOC) to characterize tumor metastasis and the development of intrinsic chemotherapeutic resistance. The research team, comprised of experts from MD Anderson and...